The efficacy of black cumin seed (Nigella sativa) oil and hypoglycemic drug combination to reduce HbA1c level in patients...

By Akrom
The efficacy of black cumin seed (Nigella sativa) oil and hypoglycemic drug combination to reduce HbA1c level in patients...

Conference Paper · December 2017
DOI: 10.1088/1757-899X/255/1/01201

2 authors, including:

Akrom Akrom
Ahmad Dahlan University

Some of the authors of this publication are also working on these related projects:

- Development of Nigella sativa oil as immunomodulator and antioxidant for metabolic syndroms patients View project
- Nigella sativa as chemopreventive and immunomodulator View project
The efficacy of black cumin seed (*Nigella sativa*) oil and hypoglycemic drug combination to reduce HbA1c level in patients with metabolic syndrome risk

To cite this article: P N R Rachman et al 2017 IOP Conf. Ser.: Mater. Sci. Eng. 259 012018

View the article online for updates and enhancements.
The efficacy of black cumin seed (*Nigella sativa*) oil and hypoglycemic drug combination to reduce HbA1c level in patients with metabolic syndrome risk

P N R Rahman¹, Akrom², E Darmawan¹

¹Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia
²Center for Drug Information and Study, Universitas Ahmad Dahlan, Yogyakarta, Indonesia

E-mail: akmaa_uad@yahoo.co.id

Abstract. Metabolic syndrome is a condition caused by metabolic abnormalities include central obesity, atherogenic dyslipidemia, hypertension, and insulin resistance. HbA1c examination is required to study the long-term glycemic status and to patients diabetic complications of metabolic syndrome. The purpose of this study is to determine the efficacy of black cumin seed (*Nigella sativa*) oil and hypoglycemic drug combination to reduce HbA1c level in patients with metabolic syndrome risk. This research performed using an experimental randomized single-blind controlled trial design. A total of 99 patients at the Jettei Public Health Center, Yogyakarta, Indonesia with metabolic syndrome risk were divided into three groups: 1 control group received placebo and two treatment groups received black seed oil orally at a dose of 1.5 mL/day and 3 mL/day, respectively, for 20 days. The clinical conditions such as blood pressure, pulse rate, BMI, blood glucose serum and HbA1c levels were examined on day 0 and 21. The results obtained were analyzed with one-way ANOVA test. The mean of HbA1c levels of all groups before treatment was higher than the normal values and there was no significant difference in HbA1c value on day 0. Administration of 1.5 and 3 mL/day of black seed oil for 20 days decreased (p<0.05) HbA1c levels. It can be concluded that administration of black cumin seed oil and hypoglycemic drug combination for 20 days in patients at risk of metabolic syndrome may reduce to HbA1c levels.

Keywords: metabolic syndrome outpatients, black cumin seed oil, HbA1c, clinical test

Introduction

One of the public health problems in Indonesia is metabolic syndrome (MS). MS is a major risk factor for vascular and degenerative diseases, including cancer [1-3] in Indonesia. MS prevalence varies based on age, gender, and region between 11 and 24.7% [4, 5]. One of the MS diseases, diabetes mellitus, is associated with the complications of various chronic and fatal diseases. Diabetes complications cause 50% and 30% of deaths due to coronary heart disease and kidney failure respectively. Diabetes also causes disability, in which 30% of patients experienced blindness due to retinopathy complications and 10% of them had to undergo leg amputation [6]. Diabetes mellitus is also associated with sudden death incidence in the
community [7]. Epidemiologically and clinically, it has been demonstrated that angiopathic complication is associated with high hemoglobin A1c (HbA1c) levels.

HbA1c levels considered safe are about 6.5-7%. It is one of the glycosylated proteins to form HbA1c. Glycosylation occurs spontaneously in the circulation and will increase when blood glucose levels are high [2]. HbA1c was the average blood glucose level for 2-3 months [2, 8]. More than 50% of diabetes mellitus patients experience failure to control blood glucose levels that lead to HbA1c levels abnormality (>7%) [9]. High blood glucose or HbA1c levels causes oxidative stress that damages blood vessels and triggers vascular endothelial death [10, 11]. HbA1c is formed from a bond of glucose with an amide group on the valine amino acid at the end of the Hb globulin beta chain. If this condition is prolonged, irreversible advanced glycosylation and products (AGE) will be formed on the walls of blood vessels that may be potentially pathogenic and lead to diabetic complications [12, 13]. Increased AGE results in cellular and tissue oxidative stress, causing damage to tissues and blood vessel cells, especially the endothelium tissue and generating an inflammatory reaction [10, 14].

Oral hypoglycemic drugs (OHOs), which are standard therapy for controlling blood glucose in DM patients, are estimated to be only capable of lowering HbA1c by approximately 0.5-2%, depending on the type of individual OHO drugs [9]. Therefore, it is often necessary for additional or complementary therapies to improve the achievement of ideal HbA1c levels of <7% [8, 15]. It is expected that a combination of high antioxidant food diet and OHOs therapy will lower HbA1c levels [12, 16]. Black cumin seed (Nigella sativa) oil (BCSO) has empirically been used as a dietary supplement, antioxidant medicinal ingredients, and immunomodulators. BCSO contains thymoquinone, nigellone, thymohydroquinone, dithymoquinone, thymol, carvacrol, nigellene, nigellimine-N-oxide, nigellidine and alpha hydrid which are empirically and laboratorially antioxidantive [17]. In preclinical studies, it has been demonstrated that BCSO administration on Danforth’s short tail (SD) mice induced by alloxan can prevent damage to the pancreas and the liver by increasing the p53 gene expression [18]. It is safe and well-tolerated in phase 1 trial [19]. BCSO administration as an adjunctive therapy in hyperlipid and hyperglycemic patients at hospital could significantly reduce total cholesterol, LDL and fasting blood glucose levels. However, the effect of BCSO on HbA1c in patients with risk of metabolic syndrome at Public Health Center has never been investigated. Therefore, this study aims to investigate the effect of black cumin seed oil on HbA1c in Public Health Center outpatients with the risk of metabolic syndrome [20].

2. Materials and Methods
This study was a randomized control trial with two dose levels. The number of samples was determined according to the phase 2 clinical trial guidelines, where the sample number was 80-300 volunteers. A total of 99 subjects with metabolic syndrome were divided into three groups, 33 subjects of each which would receive BCSO at dose of 1.5 mL/day and 3 mL/day for 20 days.

Research subjects were outpatients at risk of metabolic syndrome at Jetis 1 Public Health Center, Bantul, Yogyakarta, Indonesia. The inclusion criteria were male or female patients aged >18 years old, willing to become research volunteers proven by voluntarily signing of informed consent, having been diagnosed with diabetes mellitus or dyslipidemia or hypertension with or without central obesity and having become the outpatient at Jetis 1 Public Health Center at least for three months. Exclusion criteria were drop out volunteers, pregnant women, taking NSAID medications and immunomodulatory supplements, allergic with black cumin seed oil, having a history of chronic kidney disease and cancer, undergoing hyperthyroid and diabetic ulcers therapy and active pulmonary TB patients. For 20 days, groups 1 and 2 were given 1.5 mL/day and 3 mL/day of BCSO soft capsule, respectively, while group 3 acts as a placebo group. This clinical trial research protocol has been reviewed and endorsed by the medical research ethics committee of the Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Yogyakarta, Indonesia. The selection of prospective research subjects was based on outpatient computer database at the Public Health Center. From the database, it was found that from May
to October 2016, there were 650 patients at risk of metabolic syndrome. The patients’ medical records containing information about hypertension, dyslipidemia, or diabetes mellitus with or without obesity were listed and screened to ensure that the medical records data met the inclusion criteria. A total of 120 patients met the criteria, and they were subsequently designated as subject candidates. All prospective subjects were gathered and briefed on general research objectives and benefits and the specific benefits and consequences of participating as research volunteers. Candidates who were willing to participate in the study were required to give consent by signing the informed consent. A total of 112 prospective subjects who have signed the informed consent then underwent physical and laboratory checks. Based on the baseline examination, 13 patients met the exclusion criteria.

The research was conducted at Jatis I Public Health Center, Bantul, Yogyakarta for 10 months from March to December 2016. The research instrument used was a spectrophotometer to measure blood glucose level, while the test material used was BCSO soft capsules containing standardized black cumin seed oil with a composition of: 2.72% thymoquinone and 0.15% caprylic fatty acid, caprat 0.1%, laurat 0.18%, miristat 12.27%, palmitate 0.28%, stearate 7.99%, oleate 0.07%, linoleat 2.85%, eicosanoate 3.15%, eicosenate 0.25%, eicosadinoate 0.03%, arachidonate 0.03%, eicopentanoate 0.03%, behenate 0.06%, docoehanoate 0.04%, 0.02% terecnoanoate and placebo in the form of empty capsules.

A total of 99 subjects were divided into three simple randomized groups (with a lottery system). Randomization was done manually by comparison between groups of 1:1:1. Random grouping was done by pharmacist with multiple lot sweepstakes. All subjects were recorded based on sequence number and then divided into three groups: treatment group 1, treatment 2 and placebo group. The drawing was done by taking number 1, 2, and 3. The number obtained by the first drawer acts as the treatment group 1, the number obtained by the second drawer as the treatment group 2, and the number obtained by the last drawer as the treatment group 3. The members of each group were selected using a multiple of 3 of the lottery number obtained. If the first lottery gets the number 1, then the members of the treatment group 1 were 4, 7, 10 and so on until the quota of 33 patients was reached. The same method applied to treatment group 2 and treatment group 3 (placebo).

The treatment given to the subjects was soft capsule (SC) of BCSO with doses of 1.5 and 3 mL/day or placebo. BCSO capsules were prepared by the pharmaceutical industry with Good Manufacturing Practices (GMP) certificate. The material was tested to examine the heavy metal content and standardization of the thymoquinone content. The capsule administration was done by doctors at Jatis I Public Health Center. The examination of post-treatment clinical conditions was done also by the doctors every two weeks at Public Health Center. Specifically trained teams were required to make visits to patients' homes twice per week to check blood pressure, pulse, and body mass index, and monitor unexpected reactions and medication compliance. The analysts and research personnel have been trained in the procedures as written in the protocol.

Vital signs, Random Blood Glucose (RBG) and HbA1c levels were examined on day 0 (to serve as baseline data) and 21. The peripheral blood was taken from the cubital vein by the previously trained Public Health Center laboratory analyst. From the collected blood, RBS and HbA1c were measured. Blood pressure, pulse and BMI were checked using tools that have been calibrated by the Calibration and Testing Laboratory of Universitas Ahmad Dahlan. RBS and HbA1c measurements were performed by the Public Health Center laboratory with 5010 spectrophotometer. The brief procedure of HbA1c measurement was as follows: 10 μL of blood plasma was put into the reaction tube, and then added with 1 mL of glucose reagent. After 10 minutes, the patients' blood glucose plasma was measured with a 5010 spectrophotometer. The results were then used to calculate the HbA1c value by the following formula:

\[ \text{HbA1c} = \frac{(\text{Glucose Plasma} + 77.3)}{35.6} \]

Demographic characteristics were presented descriptively. The mean comparison test was performed on the measurement data of blood pressure, pulse, BMI, serum glucose level, and
HbA1c levels 17 day 0 and day 21 with one-way ANOVA using SPSS free edition software (SPSS version 16) with 95% confidence level.

3. Result and Discussion

3.1 Characteristics of research subjects

Four hundred and one diabetes mellitus patients and 615 hypertensive patients who underwent treatment at Jetis I Public Health Center, Bantul, based on the recommendation of the treating physicians, 120 prospective subjects fulfilled the inclusion criteria.

| Characteristics       | Treatment Group |           |           |           |           |
|-----------------------|-----------------|-----------|-----------|-----------|-----------|
|                       | Placebo group   | Group 1   | Group 2   |           | p-value   |
| n = 33                | n = 33          | n = 33    | n = 33    |           |           |
| Gender                |                 |           |           |           |           |
| Men                   | 9               | 7         | 7         | 0.802     |
| Women                 | 24              | 26        | 26        |           |           |
| Age (years)           |                 |           |           |           |           |
| ≤55 years old         | 14              | 14        | 15        | 0.582     |
| > 56 years old        | 19              | 16        | 18        |           |           |
| Education             |                 |           |           |           |           |
| ≤Junior HS            | 19              | 21        | 19        | 0.999     |
| Senior HS ≤           | 14              | 12        | 14        |           |           |
| Occupation            |                 |           |           |           |           |
| Civil servants        | 1               | 0         | 3         | 0.141     |
| Entrepreneur          | 5               | 3         | 5         |           |           |
| Farmers               | 4               | 3         | 5         |           |           |
| Private Sector        | 1               | 2         | 2         |           |           |
| Labor                 | 5               | 7         | 4         |           |           |
| Fishermen             | 1               | 0         | 4         |           |           |
| Unemployed            | 11              | 11        | 5         |           |           |
| etc.                  | 5               | 7         | 5         |           |           |
| Marital Status        |                 |           |           |           |           |
| Married               | 32              | 32        | 33        | 0.608     |
| Single                | 1               | 1         | 0         |           |           |

All prospective subjects were then gathered and briefed and asked to sign the informed consent, but only 112 patients were willing to become research subjects. Demographic and clinical characteristics are presented in Table 1 & 2. Table 1 shows that based on gender, age, education, occupation, marital status, and therapy type, there were no differences among groups (p>0.05). Most of the subjects were junior high school female graduates and aged over 50 years old.

Most subjects received more than one drug therapy, with most patients receiving a combination therapy of 1 OHO and 1 antihypertensive drugs, followed by patients with a single OHO drug, patients with two OHO drugs, and patients with 2 OHO drugs and 1 antihypertensive medication.
Table 2. Type of drug therapy prescribed by doctors

| Type of single and combination therapy for patients at risk of metabolic syndrome | Treatments Group | p-value |
|---------------------------------------------------------------------------------|------------------|--------|
|                                                                                  | Placebo group    | Group 1 | Group 2 |
|                                                                                  | (n = 33)         | (n = 33) | (n = 33) |
| 1 diabetes drug                                                                 | 6                | 11      | 6       | 0.333 |
| 1 hypertensive drug                                                             | 0                | 0       | 1       |       |
| 1 dyslipidemia drug                                                             | 0                | 1       | 0       |       |
| 2 diabetes drugs                                                                | 5                | 6       | 6       |       |
| 2 hypertensive drugs                                                            | 0                | 1       | 0       |       |
| 3 diabetes drugs                                                                | 0                | 0       | 1       |       |
| 1 diabetes drug + 1 hypertensive drug                                           | 14               | 4       | 7       |       |
| 1 diabetes drug + 1 dyslipidemia drug                                           | 0                | 1       | 1       |       |
| 1 diabetes drug + 2 hypertensive drugs                                          | 0                | 3       | 1       |       |
| 2 diabetes drugs + 1 hypertensive drug                                          | 5                | 3       | 4       |       |
| 2 diabetes drugs + 1 dyslipidemia drug                                          | 1                | 0       | 0       |       |
| 2 diabetes drugs + 2 hypertensive                                              | 1                | 3       | 3       |       |
| 3 diabetes drugs + 1 hypertensive drugs                                         | 1                | 0       | 0       |       |
| 1 diabetes drug + 1 hypertensive drug + 1 dyslipidemia drug                     | 0                | 0       | 1       |       |
| 1 diabetes drug + 1 hypertensive drug + 2 dyslipidemia drug                     | 0                | 0       | 1       |       |
| 2 diabetes drugs + 1 hypertensive drug + 1 dyslipidemia drug                    | 0                | 0       | 1       |       |

3.2. Measurement results of clinical conditions and HbA1c levels on day 0

Subjects' clinical conditions (blood pressure, pulse rate, BMI, glucose serum level and HbA1c on day 0) (before treatment) are shown in Table 3.

Table 3. Blood pressure, pulse, BMI, serum glucose level and HbA1c on day 0

| Vital Signs                             | Placebo group | Group 1        | Group 2 | p-value |
|-----------------------------------------|---------------|----------------|---------|---------|
|                                        | (n = 33)      | (n = 33)       | (n = 33)|
| Systolic (mmHg)                         | 142.48±16.42  | 141.73±16.84   | 143.64±18.63 | 0.903  |
| Diastolic (mmHg)                        | 79.76±7.005   | 80.52±9.138    | 81.09±9.531 | 0.821  |
| Pulse                                  | 89.29±9.997   | 89.33±10.764   | 90.82±11.246 | 0.816  |
| BMI (Kg/m²)                             | 24.15±4.103   | 23.76±4.346    | 24.53±3.8  | 0.749  |
| Serum Glucose Level (mg/dL)             | 266.93±123.99 | 233.66±100.94  | 273.03±126.40 | 0.070 |
| HbA1c (%)                               | 9.30±8.057    | 8.56±2.777     | 9.34±3.295 | 0.524  |

The results of vital signs and HbA1c measurement on day 0 show that there was no significant difference (p > 0.05) in blood pressure, pulse, BMI, glucose serum level, and HbA1c levels prior to BCSDO administration. Before the treatment, subjects’ mean of blood glucose and HbA1c levels exceeded the normal values of RBS with >200 mg/dL and HbA1c with >7%. The mean systolic blood pressure (SBP) also exceeded the normal value with >140 mmHg, but the mean diastolic blood pressure (DBP) was relatively normal with <90 mmHg [8].

3.3. Measurement results of clinical condition and HbA1c on day 21

The measurement results of clinical conditions (blood pressure, pulse rate, BMI, blood glucose serum) and HbA1c levels on day 21 are presented in Table 4.
Table 4. Measurement results of clinical conditions and HbA1c levels on day 21

| Vital Signs               | Treatments Group | P-value |
|---------------------------|-------------------|---------|
|                           | Placebo group (n = 33) | Group 1 (n = 33) | Group 2 (n = 33) |         |
| Systolic (mmHg)           | 138.66±13.170      | 136.10±15.946   | 139.81±17.662   | 0.636   |
| Diastolic (mmHg)          | 75.31±8.476        | 79.52±17.160    | 80.87±9.804     | 0.182   |
| Pulse                     | 89.66±11.085       | 90.26±10.155    | 93.87±14.440    | 0.330   |
| BMI (Kg/m²)               | 24.55±4.363        | 24.04±4.393     | 25.31±3.881     | 0.493   |
| Serum glucose level (mg/dL)| 270.31±80.324      | 190.19±88.304   | 199.61±91.172   | 0.001   |
| HbA1c (%)                 | 9.60±2.260         | 7.44±2.487      | 7.51±2.492      | 0.001   |

2 There was a significant difference between the placebo group and group 1.
3 There was a significant difference between the placebo group and group 2.
4 There was no significant difference between group 1 and group 2.

Table 4 shows that after 20 days of BCSO treatment, there was no difference in blood pressure, pulse rate, and BMI between the treatment groups, with significance values of p > 0.05. It shows that the BCSO administration can lower blood pressure to the target level defined for patients with diabetes mellitus by the American Diabetes Association (ADA) and the American Heart Association (AHA) [8], i.e., < 140/90 mmHg. However, the result has not met the therapeutic target defined by the International Diabetes Mellitus Federation (IDF) (2006) that recommends a blood pressure target of <135/85 mmHg. There has been a decrease in the mean TDS, i.e., TDS < 140 mmHg, although not statistically significant (p > 0.05). Research data also shows that there is no change in average pulse in all groups, and the mean pulse is in accordance with the normal target range according to the American Heart Association (60-100x/min). The average BMI in the three groups after the treatment was relatively similar (p > 0.05), categorized as non-obese according to the American Heart Association [8]. The results of this study are not entirely consistent with previous studies, which stated that administering black cumin seed extract (BCSE) with a dose of 500 mg for 8 weeks could lower blood pressure in patients with metabolic syndrome [21]. Differences in terms of intervention timing, intervention type, subjects’ initial condition, and research setting contribute to the differences in clinical outcomes. Provided an 8-week BCSO intervention for patients with metabolic syndrome in hospitals, whereas this study provided a 20-day BCSO intervention in patients at risk of metabolic syndrome in Public Health Center [21].

The results showed that there was an average decrease of RBS and HbA1c levels after BCSO treatment for 20 days, and there was a difference in the average values of RBS and HbA1c levels among the three treatment groups (p < 0.01). There were significant differences in HbA1c and RBS values between the control group and treatment group 1 and treatment group 2 (p < 0.01), but there was no significant difference between treatment group 1 and treatment group 2 (p > 0.05). However, despite a decline in the mean HbA1c value of the treatment groups, the results are not yet capable of reaching the targets defined by the American Diabetes Association (<7%). These results are in line with previous studies, which revealed that the administration of BCSO extract with a dose of 500 mg or BCSE oil with a dose of 2.5 mL/day for 8 weeks could decrease HbA1c and RBS levels in patients with metabolic syndrome [21].

BCSO can lower the HbA1c value because it increases insulin production, decreases insulin resistance, stimulates cellular activity, and decreases intestinal insulin absorption [22]. High thymoquinone content in BCSO has antioxidant effect that can decrease oxidative stress to prevent further cell damage [22, 23]. Consumption of 2 g/day of black cuminseed combined with oral hypoglycemic drugs can improve the effectiveness of endogenous antioxidant and enzyme therapy [24]. High blood glucose and HbA1c levels have been shown to be associated with increased incidence of death and cardiovascular disease [25]. Furthermore, the antioxidant diet has been shown to inhibit degenerative processes, reduce risk of and death from cardiovascular disease, and prolong life [16, 26-27].
1 Conclusion
Black cumin seed oil treatment with doses of 1.5 and 3 mL/day for 20 days in patients at risk of metabolic syndrome affects HbA1c activity (p<0.05) by reducing its level.

Phase III Clinical Trial of BCOSO needs to be done in patients at risk of metabolic syndrome with longer administration time as an attempt to obtain phytopharmaca (phytomedicines) for secondary prevention of cardiovascular disease incidence in primary care.

Acknowledgement
The researchers would like to thank the Ministry of Research and Technology and Higher Education for providing the financial aid through Hibah Pascasarjana scheme (no. PPS-058/SP3/III/2016), the research subjects, the staff at Jetis I Public Health Center, Bantul, Yogyakarta, Indonesia and all members of the research team.

References
[1] Aru W S D 2006 Buku Ajar Ilmu Penyakit Dalam Jilid III Edisi IV Penerbit Ilmu Penyakit Dalam FKUI Jakarta Barat.
[2] Leon B M and Maddox T M 2015 Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research World J. Diabetes 6 (13) 1246-1258.
[3] Planterpan L, Mercedes R, Canethon, Yun W, Anthony J G, Hanley, Atephon P F, Stephen M H and Lynne W 2004 Predictors of the incident metabolic syndrome in adults: the insulin resistance atherosclerosis study Diabetes Care 3 788-793.
[4] Kamso S 2007 Metabolic Syndrome in the Indonesian elderly Medical Journal of Indonesia 16 (23) 195-200.
[5] Sudijanto K, Purwantyastuti P, Dharmayanti U L, Ratna J, Yull K R and Besral Besral 2011 Prevalensi dan determinan sindrom metabolik pada kelompok eksekutif di jakarta dan sekintanya Jurnal Kesehatan Masyarakat Nasional 6 (2) 85-90.
[6] Soegono 2008 Hidup secara mandiri dengan diabetes melitus, kencing manis, sakit gula, FK UI, Jakarta.
[7] Siscovick D S 2015 Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community Rev. Endocr. Metab. Disord. 11 (1) 53–59.
[8] Fox C S, Golden S H, Anderson C, Bray G A, Burke L E, de Boer I H, Deedwania P, Eckel R H, Ershow A G, Fradkin J, Inzucchi S E, Kosiborod M, Nelson R G and Patel M J 2015 Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the american heart association and the american diabetes association Diabetes Care 38 1777–1803.
[9] Khattaba M, Khabier Y S, Al-Khawaldeh A and Ajlouni K 2010 Factors associated with poor glycemic control among patients with Type 2 diabetes J. Diabetes Complications 24 84–89.
[10] Kayama Y, Raaz U, Jagger A, Adam M, Schellinger I N, Sakamoto M, Suzuki H, Toyama K, Spin J M and Tsao P S 2015 diabetic cardiovascular disease induced by oxidative stress Int. J. Mol. Sci. 16 (10) 25234-25263.
[11] Srikanthan K, Feyh A, Visweshwar H, Shapiro J I and Sodhi K 2015 Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginia Population Int. J. of Med. Sci. 13 (1) 25-38.
[12] Bajaj S and Khan A 2012 Antioxidants and diabetes Indian J. Endocrinol. Metab. 16 Supplement 2 S267-S271.
[13] Kusmiyah Y, Nusriswati and Rahayu U 2010 Hubungan tingkat self care dengan tingkat HBAlc pada klien diabetes melitus type 2 di Poliklinik Endokrin RSUP Dr. Hasan Sadikin Bandung.
[14] Zhao D, Yang J and Yang L. 2017 Insights for oxidative stress and mtor signaling in myocardial ischemia/reperfusion injury under diabetes *Oxidative Medicine and Cellular Longevity*.

[15] Andrews M, Angone K M, Cray J V, Lewis J A and Johnson P H. 1999 Nurses of alternative and complementary therapies.

[16] Zhou M, Zhu L, Cui X, Peng L, Zhao X, He S, Ping F and Li W. 2016 Influence of diet on leukocyte telomere length, markers of inflammation and oxidative stress in individuals with varied glucose tolerance: a Chinese population study *Nutrition J.* 15:39.

[17] Bashandy 2007 Effect of fixed oil *Nigella sativa* on male fertility normal and hyperlipidemic rats *B. J. Pharmocol.* 3 (1) 27-33.

[18] Akrom, Darmawan E and Yuliyah, I. 2015 Black cumin seed oils hepatoprotector in decreasing SGPT and SGOT activity and increasing p53 gene expression in sprague dawley rats induced by alloxan *JPHIS* 4 (3) 159-163.

[19] Akrom and Darmawan E 2017 Tolerability and safety of black cuminseed oil (BSCO) administration for 20 days in healthy subjects *Biomed. Res.* 128 (9) 4196-4201.

[20] Najmi A, S F Haque, M Nasiruddin and R A Kha. 2008 Effect of *Nigella sativa* oil on various clinical and biochemical parameters of metabolic syndrome *Int. J. Diabetes & Metab.* 16 85-87.

[21] Najmi A, Nasiruddin M, Khan R A and Haque S F 2012 Indigenous herbal product *Nigella sativa* proved effective as an antihypertensive in metabolic syndrome 6 (1).

[22] Bamosa and Abdullah O 2015 A Review on the hypoglycemic effect of *Nigella sativa* and thymoquinone *Saudi J. Med. Med. Sci.* 3 (1) 2-7.

[23] Akrom 2013 Mekamisne kemopreventif ekstrak heksan BJH pada tikus SD diinduksi DMBA: kajian antioksidan dan immunomodulator *Disertasi Program Doktor Ilmu Kedokteran dan Kebersihan FK UGM Yogyakarta*.

[24] Kautubi H, Bamosa A O, Badar A, Al-EIq A, Abou-Hozafa B and Lebda F. 2015 *Nigella sativa* improves glycemic control and ameliorates oxidative stress in patients with type 2 diabetes mellitus: placebo controlled participant blinded clinical trial *PLoS ONE* 10 (2) 1-15.

[25] Svensson E, Bergesen L M, Johnsen S P, Pedersen L, Norrelund H and Buhl E S. 2017 Early glycemic control and magnitude of hba1c reduction predict cardiovascular events and mortality: population-based cohort study of 24,752 Metformin Initiators *Diabetes Care* 40 800–807.

[26] Snyder M and Lindsquit 2002 Complementary/alternative therapies in nursing 4th ed, Springer.

[27] Carneiro A and Andrade J P. 2017 Nutritional and lifestyle interventions for age-related macular degeneration: A review, *oxidative medicine and cellular longevity*, Article ID 6469138, 1-13.
The efficacy of black cumin seed (Nigella sativa) oil and hypoglycemic drug combination to reduce HbA1c level in patients...

### Originality Report

**% Similarity Index**: 19%

### Primary Sources

| # | Source | Title                                                                 | Words | % Similarity |
|---|--------|-----------------------------------------------------------------------|-------|--------------|
| 1 | D R Fajar, Akrom, E Darmawan. | "The influence of black cumin seed oil therapy with dosage of 1.5 mL/day and 3 mL/day to interleukin-21 (IL-21) expression of the patients with metabolic syndrome risk", IOP Conference Series: Materials Science and Engineering, 2017 | 269   | 7%           |
| 2 | openaccess.city.ac.uk | | 111   | 3%           |
| 3 | halshs.archives-ouvertes.fr | | 53    | 1%           |
| 4 | fdi2013istanbul.org | | 41    | 1%           |
| 5 | D A Derusova, V P Vavilov, S S Pawar. | "Evaluation of equivalent defect heat generation in carbon epoxy composite under powerful ultrasonic stimulation by using infrared thermography", IOP Conference Series: Materials Science and Engineering, 2015 | 28    | 1%           |
| 6 | L Jing, B Hu, J Li, T Noland, H Guo. | "Automated tree crown delineation from imagery based on morphological techniques", IOP Conference Series: Earth and Environmental Science, 2014 | 21    | 1%           |
| 7 | journal.uad.ac.id | | | |
James S McLay, John J McMurray, Alan B Bridges, Callum G Fraser, Allan D Struthers. "Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure", American Heart Journal, 1993

Aljabre, S.H.M.. "Antidermatophyte activity of ether extract of Nigella sativa and its active principle, thymoquinone", Journal of Ethnopharmacology, 20051003

M. GABRIEL KHAN. "Diabetes and Cardiovascular Disease", Elsevier BV, 2006

Warsi, A R Sholichah. "Phytochemical screening and antioxidant activity of ethanolic extract and ethyl acetate fraction from basil leaf (L.) by DPPH radical scavenging method", IOP Conference Series: Materials Science
L H Nurani, A Mursyidi, S Widyarini, A Rohman. "The effects of combination of Jack ethanolic extract and doxorubicine on hematological profile in rats given by 7,12-dimethylbenz(a)anthracene", IOP Conference Series: Materials Science and Engineering, 2017.

www.ncbi.nlm.nih.gov

"13th European Congress of Clinical Microbiology and Infectious Diseases", Clinical Microbiology and Infection, 2003.

Qiu, Chunhui, Zhiqiang Fu, Yaojun Shi, Yang Hong, Shengfa Liu, and Jiaojiao Lin. "A retinoid X receptor (RXR1) homolog from Schistosoma japonicum: Its ligand-binding domain may bind to 9-cis-retinoic acid", Molecular and Biochemical Parasitology, 2013.

www.science.gov

Taner, Pelin, Ahmet Ergin, M. Murad Basar, Ertan Batislam, and Yasemin K. Bilgili. "Sildenafil Does Not Alter Retrobulbar Hemodynamics in Postural Variations", Neuro-Ophthalmology, 2005.

circ.ahajournals.org

www.medsci.org
